Clarus Therapeutics Holdings, Inc. (CRXT)

NASDAQ: CRXT · IEX Real-Time Price · USD
0.0475
-0.0215 (-31.16%)
At close: Sep 5, 2022 11:00 PM
0.0656
+0.0181 (38.11%)
Pre-market: Sep 6, 2022 7:39 AM EST
Market Cap 2.47M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out n/a
EPS (ttm) -2.80
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,737,134
Open 0.065
Previous Close 0.069
Day's Range 0.0475 - 0.0749
52-Week Range n/a
Beta n/a
Analysts Buy
Price Target 3.06 (+6,342.1%)
Earnings Date Aug 15, 2022

About CRXT

Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen therapies for inflammatory breast disease and certain forms of breast cancer; and license agreement with The Royal Institution for the Advancement of Learning/McGill University to... [Read more]

Industry Pharmaceuticals
Founded 2003
Employees 16
Stock Exchange NASDAQ
Ticker Symbol CRXT
Full Company Profile

Financial Performance

In 2021, CRXT's revenue was $13.96 million, an increase of 119.14% compared to the previous year's $6.37 million. Losses were -$40.21 million, 289.0% more than in 2020.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for CRXT stock is "Buy." The 12-month stock price forecast is 3.06, which is an increase of 6,342.11% from the latest price.

Price Target
$3.06
(6,342.11% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Clarus Therapeutics Holdings, Inc. Announces Plan for Near-Term Sale of JATENZO® Using Structured Process Through Cha...

Bidding process and auction for JATENZO (testosterone undecanoate capsules; C-III) projected to conclude late October 2022 Bidding process and auction for JATENZO (testosterone undecanoate capsules; C-I...

2 months ago - GlobeNewsWire

Clarus Therapeutics (CRXT) Stock Plunges Ahead of Aug. 31 Delisting

Source: arfa adam / Shutterstock.com Clarus Therapeutics (NASDAQ: CRXT ) stock is falling hard on Monday as investors prepare for the stock to be delisted later this week. Shares of CRXT stock will no l...

3 months ago - InvestorPlace

Clarus Therapeutics Reports Second Quarter 2022 Financial and Operating Results and Announces Workforce Reduction

Second quarter 2022 net revenue increased 46% year-over-year to $4.1 million

3 months ago - GlobeNewsWire

Clarus Therapeutics Announces Notice of Allowance for Additional Patent Claims Covering JATENZO® (testosterone undeca...

JATENZO is the first and only FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions

4 months ago - GlobeNewsWire

Clarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at ENDO 2022, the Endocrine Society's...

JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions

5 months ago - GlobeNewsWire

Clarus Therapeutics Announces Issuance of Patent Covering JATENZO® (testosterone undecanoate)

JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions

6 months ago - GlobeNewsWire

Clarus Therapeutics Reports First Quarter 2022 Financial and Operating Results

First quarter 2022 net revenue increased 72% year-over-year to $4.0 million

6 months ago - GlobeNewsWire

Clarus Therapeutics to Report First Quarter 2022 Financial and Operating Results

NORTHBROOK, Ill., May 12, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (“Clarus”) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advanc...

6 months ago - GlobeNewsWire

Clarus Therapeutics Announces Notice of Allowance for Patent Claims Covering CLAR-121 (Testosterone + Anastrozole) fo...

Initial focus for CLAR-121 is the treatment of periductal mastitis (PDM) in women

6 months ago - GlobeNewsWire

Clarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at the 2022 American Urological Assoc...

JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions

6 months ago - GlobeNewsWire

Clarus Therapeutics Announces Notice of Allowance for Patent Claims Covering JATENZO® (testosterone undecanoate)

JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions

7 months ago - GlobeNewsWire

Clarus Therapeutics Announces Closing of Upsized $30.0 Million Underwritten Public Offering

NORTHBROOK, Ill., April 27, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advanc...

7 months ago - GlobeNewsWire

Why Clarus Therapeutics Shares Are Getting Hammered

Clarus Therapeutics Holdings Inc (NASDAQ: CRXT) shares are trading lower by 52.82% at $0.85 after the company announced an upsized $30 million underwritten public offering at $1.10 per share.  The offer...

7 months ago - Benzinga

Clarus Therapeutics Announces Pricing of Upsized $30.0 Million Underwritten Public Offering

NORTHBROOK, Ill., April 25, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advanc...

7 months ago - GlobeNewsWire

Clarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at the Androgen Society 4th Annual Me...

JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions

7 months ago - GlobeNewsWire

Clarus Therapeutics Reports Fourth Quarter and Full Year 2021 Financial and Operating Results

2021 net revenue increased 119% year-over-year to $14.0 million

8 months ago - GlobeNewsWire

Clarus Therapeutics to Report Fourth Quarter and Full Year 2021 Financial and Operating Results

NORTHBROOK, Ill., March 29, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (“Clarus”) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by adva...

8 months ago - GlobeNewsWire

Clarus Announces Initiation of Phase 4 Clinical Trial of JATENZO® (testosterone undecanoate) for the Treatment of Hyp...

JATENZO is the first and only FDA-approved oral softgel for testosterone (T) replacement therapy in adult males who have deficient T due to certain medical conditions

8 months ago - GlobeNewsWire

Clarus Therapeutics to Present at the Oppenheimer 32nd Annual Healthcare Conference

NORTHBROOK, Ill., March 10, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advanc...

8 months ago - GlobeNewsWire

Clarus Announces Strategic Partnerships for JATENZO® (testosterone undecanoate) with Vault Health and AssistRx – Lead...

JATENZO is the first and only FDA-approved oral softgel capsule for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions

9 months ago - GlobeNewsWire

Clarus Therapeutics Appoints Dr. Zhanna Jumadilova as Chief Clinical Development Officer

Dr. Jumadilova most recently led clinical development programs at Insmed and Pfizer and has nearly 30 years of combined pharmaceutical and biotech experience

10 months ago - GlobeNewsWire

Clarus Therapeutics Announces Closing of Approximately $15 Million Private Placement

Proceeds to support the ongoing commercialization of JATENZO® (testosterone undecanoate)

11 months ago - GlobeNewsWire

Clarus Therapeutics Announces $15 Million Private Placement

Proceeds to support the ongoing commercialization of JATENZO® (testosterone undecanoate)

1 year ago - GlobeNewsWire

Clarus Therapeutics Announces Issuance of Two New Patents for JATENZO® (testosterone undecanoate)

JATENZO is the first and only FDA-approved oral softgel for testosterone replacement therapy (TRT) in adult males who have deficient testosterone due to certain medical conditions

1 year ago - GlobeNewsWire

Clarus Therapeutics Reports Third Quarter 2021 Financial and Operating Results

Third quarter 2021 revenue increased 93% year-over-year to $4.3 million

1 year ago - GlobeNewsWire